Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Retained Earnings (2023 - 2025)

Kura Oncology (KURA) has disclosed Retained Earnings for 3 consecutive years, with -$1.2 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 31.12% to -$1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Dec 2025, down 31.12% year-over-year, with the annual reading at -$1.2 billion for FY2025, 31.12% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.2 billion at Kura Oncology, down from -$1.1 billion in the prior quarter.
  • The five-year high for Retained Earnings was $1.1 million in Q3 2024, with the low at -$1.2 billion in Q4 2025.
  • Average Retained Earnings over 3 years is -$667.8 million, with a median of -$796.4 million recorded in 2024.
  • The sharpest move saw Retained Earnings surged 100.16% in 2024, then tumbled 98047.04% in 2025.
  • Over 3 years, Retained Earnings stood at -$1.3 million in 2023, then plummeted by 70350.2% to -$895.4 million in 2024, then crashed by 31.12% to -$1.2 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.2 billion, -$1.1 billion, and -$1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.